Physicians Slow To Adopt Newer Drugs For Atrial Fibrillation

October 26, 1998

American physicians treating patients with atrial fibrillation, a type of arrhythmia or irregular heartbeat that can lead to stroke, are slow to incorporate newer medications into their practice, according to a study from the Massachusetts General Hospital (MGH). The report in the Oct. 26 issue of Archives of Internal Medicine looked at physicians' rates of prescribing two types of antiarrhythmic medications and found that older medications continue to be used in most patients, even though newer options may be more effective and have fewer side-effects. They also found that overall usage of these medications may be too low.

"Physician's practices appear to be guided more by tradition than by the latest science," says Randall Stafford, MD, PhD, of the MGH Institute for Health Policy and General Medicine Division, who led the study. "We think our study points out the need for better treatment guidelines and physician education."

Atrial fibrillation, an abnormal rhythm in the contraction of the upper chambers of the heart, is the strongest common risk factor for stroke. Antiarrhythmic medications, which directly address heart rhythm problems, fall into two categories: rate control medications, which slow the irregular heartbeat, and sinus rhythm medications, which attempt to restore normal heart rhythm.

The research team used data from the National Ambulatory Medical Care Survey from 1980 to 1996 to track trends in prescribing antiarrhythmics. Based on information from 1,555 office visits by patients with atrial fibrillation, they found an overall decrease in prescriptions for both kinds of drugs. Prescriptions for rate control drugs dropped from 79 percent of visits in 1980-81 to 62 percent in 1994-96. Sinus rhythm drugs were prescribed in 18 percent of 1980-81 visits, dropped to 4 percent in 1992-93, but then increased to 13 percent in 1994-96.

Among prescriptions for rate control drugs, digoxin (digitalis) continues to be the most commonly prescribed drug, although prescriptions for beta blockers and calcium channel blockers increased during the study period. Digoxin, the research team noted, has several limitations not found in beta blockers and calcium channel blockers. For example, patients taking digoxin may be more likely to experience shortness of breath when they exert themselves.

Among sinus rhythm drugs, a group of older drugs called class IA drugs were the most frequently prescribed. The significant dip in usage of sinus rhythm drugs in 1992-93 was probably due to a 1989 report of serious side effects from some sinus rhythm medications. New sinus rhythm medications with fewer side effects "class III drugs" have been introduced in recent years. However, most of the increase in usage of sinus rhythm drugs seen between 1992-93 and 1994-96 reflected greater use of the older class IA drugs.

"While there are good reasons to be cautious about adopting new medications, these results imply an inherent inertia in physician practices that does not reflect the most recent scientific information," Stafford says. "It's interesting to note that the drop in usage of class IA sinus rhythm agents after problems were reported was much more dramatic than the rate at which newer medications have been adopted. It appears that physicians react more quickly to reports of toxic reactions than they do to news of a medication's effectiveness."

Other authors of the Archives study are Daniel Singer, MD, Deborah Robson and Bismruta Misra, MPH, of the MGH General Medicine Division; and Jeremy Ruskin, MD, of the MGH Cardiac Unit. The study was supported by grants from the National Heart, Lung and Blood Institute and the Eliot B. Shoolman Fund at the MGH.
-end-


Massachusetts General Hospital

Related Atrial Fibrillation Articles from Brightsurf:

Atrial fibrillation less deadly than it used to be, but still cause for concern: BU study
A first-of-its-kind study by researchers from the Boston University School of Public Health (BUSPH) shows a decline in deaths related to atrial fibrillation (irregular heartbeat) over the last 45 years.

Postoperative atrial fibrillation does not impact on overall survival after esophagectomy
Volume 11, Issue 25 of Oncotarget reported that Administration of landiolol hydrochloride was found to be associated with reduced incidence of atrial fibrillation after esophagectomy for esophageal cancer in our previous randomized controlled trial.

People with atrial fibrillation live longer with exercise
More than 100,000 Norwegians have atrial fibrillation. They should be actively exercising for their health.

Atrial fibrillation among overweight people is not due to fat
In a recently published study, researchers from Aarhus University document that the risk of atrial fibrillation is not linked to the amount of body fat, but instead to large muscle mass, or more precisely, a high fat-free weight

Eating more protein could help ward off atrial fibrillation in women
Women who ate slightly more than the recommended daily amount of protein were significantly less likely to develop atrial fibrillation (AFib), a dangerous heart rhythm disorder that can lead to stroke and heart failure, when compared with those who consumed less protein, according to research being presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC).

Zebrafish teach researchers more about atrial fibrillation
Genetic research in zebrafish at the University of Copenhagen has surprised the researchers behind the study.

Personalized medicine for atrial fibrillation
The study, published in Europace, uses signals from implantable devices -- pacemakers and defibrillators -- to analyze electrical signals in the heart during episodes of atrial fibrillation.

Prescribing anticoagulants in the ED for atrial fibrillation increases long-term use by 30%
Patients prescribed anticoagulants after a diagnosis of atrial fibrillation in the emergency department are more likely to continue long-term use of medications to treat the condition, according to research published in CMAJ (Canadian Medical Association Journal).

Anticoagulant benefits for atrial fibrillation decrease with age
The net clinical benefit of anticoagulants for atrial fibrillation (AF) -- one of the most important causes of irregular heartbeats and a leading cause of stroke -- decreases with age, as the risk of death from other factors diminishes their benefit in older patients, according to a study led by researchers at UC San Francisco.

Research improves understanding of mechanism of atrial fibrillation
Mouse model studies show that noncoding DNA regions linked to atrial fibrillation risk can display long-range regulatory functions directed at Pitx2 gene and in this way predispose to the condition.

Read More: Atrial Fibrillation News and Atrial Fibrillation Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.